Supreme Court Sides with E-Cigarette Retailers: Judicial Review in 5th Circuit Allowed in FDA Tobacco Ban Challenge
In a major legal development that could reshape how regulatory denials by federal agencies are challenged, the U.S. Supreme Court ruled 7–2 on Friday that e-cigarette retailers can seek judicial review of the Food and Drug Administration’s (FDA) marketing denial orders (MDOs) in the U.S. Court of Appeals for the 5th Circuit. This decision opens the door for retailers—alongside manufacturers—to challenge FDA rulings that effectively bar the sale of certain tobacco-related products.
The case arose from the FDA’s decision to deny R.J. Reynolds Vapor Company (based in North Carolina) permission to market its flavored e-cigarette products. Rather than filing suit in the U.S. Court of Appeals for the D.C. Circuit or the 4th Circuit—venues typically reserved for such administrative appeals—RJR joined forces with Avail Vapor, a Texas-based retailer, and a Mississippi-based trade association representing convenience stores and gas stations that also sell RJR products. They took the fight to the 5th Circuit, asserting that the FDA’s denial would economically devastate their businesses.
🚨 Legal Background: The Smoking Prevention Act and Jurisdictional Debate
Under the Family Smoking Prevention and Tobacco Control Act (TCA), anyone “adversely affected” by an FDA denial of a marketing application may file a petition for judicial review in either the D.C. Circuit or “the circuit in which such person resides or has their principal place of business.”
The FDA argued that RJR’s principal business was in North Carolina and thus belonged in the 4th Circuit (which had already upheld similar FDA decisions). The 5th Circuit rejected that reasoning, noting that the retailers themselves had standing and were located within its jurisdiction.
The Supreme Court affirmed this view, effectively endorsing a broader interpretation of who can challenge federal regulatory decisions and where they can do so.
🧑⚖️ The Majority Opinion: Retailers Are “Adversely Affected”
Writing for the majority, Justice Amy Coney Barrett concluded that the law explicitly allows any party “adversely affected” by an FDA marketing denial to seek judicial review. That includes not just the manufacturers, but also downstream stakeholders like retailers who directly suffer economic harm.
Barrett emphasized the Court’s precedent that the term “adversely affected” should be interpreted broadly. Because retailers face significant penalties if they continue to sell products banned by the FDA—or suffer financial loss if they can’t sell them—they fall squarely within the “zone of interests” Congress intended to protect under the Tobacco Control Act.
“If the FDA denies an application, the retailers, like the manufacturer, lose the opportunity to profit from the sale of the new tobacco product—or, if they sell the product anyway, risk imprisonment and other sanctions,” Barrett wrote.
Therefore, the retailers had standing and could bring suit in the 5th Circuit, where they are based.
🧭 What the Court Didn’t Decide
Significantly, the Court did not resolve whether RJR Vapor, the manufacturer, could have independently filed in the 5th Circuit absent the retailers’ participation. The FDA did not raise this issue in lower courts, so Barrett declined to weigh in, noting that any comment would set unnecessary precedent for venue rules in similar federal lawsuits.
“Prudence counsels waiting,” Barrett said, until such a question is fully litigated.
📣 Dissenting Opinion: Too Broad, Too Far
Justice Ketanji Brown Jackson, joined by Justice Sonia Sotomayor, issued a strong dissent. Jackson argued that the majority had effectively dismantled the zone-of-interest test, allowing any downstream economic player—however far removed from the original application—to bring a legal challenge.
“Nothing in the statute suggests that Congress meant to authorize retailers to sue to challenge the FDA’s denial of a manufacturer’s marketing application,” Jackson wrote.
She further contended that allowing lawsuits outside of the designated circuits undermines the purpose of centralized judicial review in administrative law.
⚖️ Key Takeaways for Legal Professionals:
- Broadened standing: Retailers may now challenge FDA product bans if they suffer economic harm, even if they did not file the original application.
- Flexible venue interpretation: Judicial review can occur in the circuit where the adversely affected retailer or trade group operates—not just where the manufacturer is based.
- Impact on administrative law: The decision may influence challenges to other federal agency rulings, expanding who qualifies as “adversely affected.”
- Future litigation likely: As the Court sidestepped key venue issues, expect future challenges to push the limits of jurisdiction in federal regulatory cases.
This ruling will likely embolden not just e-cigarette retailers but a broader swath of regulated industries, such as pharmaceuticals, finance, and healthcare, to seek venue-friendly reviews of agency decisions.
#FDALawsuit #TobaccoLaw #EcigRegulation #AdministrativeLaw #JudicialReview #LegalUpdate #RetailLaw #BarExamReady #LegalBlog
lawrota.com 
Leave a comment